Replies to post #243102 on Avid Bioservices Inc (CDMO)

[Robert C Jonson]

The population that strongly expresses PD-1, they are the ones that had an average of 17 months.

And only 19% of those treated Opdivo:

Additionally, 19 percent of those treated with Opdivo experienced a complete or partial shrinkage of their tumors

[md1225]

Yes nuke and best of all is bavi will allow all patients to benefit from nivolumab or durvolumab we will see 20 months average mos with many CRs when Bavituximab is added.